Patent will allow the development of an industrial biomarker analysis kit which could be available worldwide Patent will allow the development of an industrial biomarker analysis kit which could be ...
- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy- NEW YORK, NY / ACCESSWIRE / July ...
All patients were included after obtaining informed consent (institutional ethic committee protocol number 3790). Training set: 57 patients in the training set had been transplanted between 2002 and ...
According to a recent review, data suggest mast cells have an important role in tissue homeostasis and wound healing, with mass cell dysregulation potentially leading to fibrotic disease. Increased ...
Orca-T significantly improved cGVHD-free survival compared to allo-HSCT, with a 78% vs 38% rate at one year. The study reported a 94% overall survival rate for Orca-T, with no new safety concerns ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Abbisko Cayman Limited revealed ...
The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared ...
FDA has approved Imbruvica (ibrutinib) to treat chronic graft versus host disease (cGVHD), a new indication for the anti-cancer drug. On August 2, 2017, FDA approved Imbruvica (ibrutinib) to treat ...
Kadmon has posted positive and more detailed data out of its so-called ROCKstar pivotal trial of KD025 in chronic graft-versus-host disease (cGVHD). The data, presented over the weekend at the 2020 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results